"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Rasmussen B, Göhring G, Bernard E, Nilsson L, Tobiasson M, Jädersten M, Garelius H, Dybedal I, Grønbaek K, Ejerblad E, Lorenz F, Flogegård M, Marcher CW, Öster Fernström A, Cavelier L, Papaemmanuil E, Ebeling F, Kittang AO, Nørgaard JM, Saft L, Möllgård L, Hellström-Lindberg E.
Rasmussen B, et al. Among authors: kittang ao.
Leukemia. 2022 May;36(5):1436-1439. doi: 10.1038/s41375-022-01537-w. Epub 2022 Mar 11.
Leukemia. 2022.
PMID: 35277655
Free PMC article.
Clinical Trial.
No abstract available.